OptimizeRx stock is back in focus after analysts reaffirmed a fair value estimate of about $24.33 per share, even as a slightly higher discount rate reflects a modest uptick in perceived risk. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback